Remove 2030 Remove Clinical Development Remove Therapies
article thumbnail

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities. These activities are pro-oncogenic (reviewed here: [link] ).

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease).

article thumbnail

Women in STEM with Gilda Ascione

Drug Target Review

At the beginning of my career, during my scholarship, I worked for two years at a research institute where I set up a research project focused on the study of metronomic oral therapies for patients with metastatic breast cancer (BC). That paper, of which I was in the authorship, remains a current point of reference for that therapy usage.

Doctors 97
article thumbnail

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. population will have obesity. About Boehringer Ingelheim.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

article thumbnail

AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases

The Pharma Data

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52